Peer Review History

Original SubmissionNovember 15, 2022
Decision Letter - Mukhtiar Baig, Editor

PONE-D-22-30145Prevalence, risk factors, and consequences of hypothyroidism among pregnant women in the health region of Lleida: a cohort studyPLOS ONE

Dear Dr. Siscart,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

ACADEMIC EDITOR: Please revise the manuscript as suggested by the reviewer.

==============================

Please submit your revised manuscript by Feb 09 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Mukhtiar Baig, Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please update your submission to use the PLOS LaTeX template. The template and more information on our requirements for LaTeX submissions can be found at http://journals.plos.org/plosone/s/latex.

3. Thank you for stating the following financial disclosure: 

"The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript"

At this time, please address the following queries:

a) Please clarify the sources of funding (financial or material support) for your study. List the grants or organizations that supported your study, including funding received from your institution. 

b) State what role the funders took in the study. If the funders had no role in your study, please state: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

c) If any authors received a salary from any of your funders, please state which authors and which funders.

d) If you did not receive any funding for this study, please state: “The authors received no specific funding for this work.”

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

4. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

5. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: https://www.youtube.com/watch?v=_xcclfuvtxQ]

6. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please delete it from any other section.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The authors write in the limitation that socioeconomic status was not evaluated, however, it was part of the objectives. It should have been included.

Overall it is a well-written manuscript.

There are no concerns regarding dual publication, research ethics, or publication ethics.

Reviewer #2: Thank you for the opportunity to review the manuscript!

While the research topic is of importance to the clinicians working with pregnant women, the manuscript needs more details and some amendments to be brought to a standard format for publication.

Introduction:

- Please indicate at the end of the introduction why you have decided to conduct this study and what is the study significance and what gaps it aimed to address.

Materials and Methods

This section needs to address the following details:

- In the presented study, pregnancies were groups into low risk, medium risk, high risk and very high risk. Usually in real practice and for the sake of providing appropriate care to each group of women, pregnancies are categorised as “low risk” and “high risk”. Please indicate why you have chosen 4 gropes? Is this what is used in the real practice in the Lleida region to provide care to the women? If not, please clarify and re-group. Please modify the

Results accordingly.

- Please provide details of how you chose the criteria for adherence, how you calculated adherence score and what each score (lower/higher) means.

Results:

- “40.4-64.7% of the treated patients showed high adherence”. Why does adherence for one single group has a range? Please clarify or amend.

Table 4:

- “Duration of the pregnancy” has subgroups of “abortion”, “pre-term”, “prolonged”, and “full-term”. Please indicate the gestational age range for each item. Also, does the word “abortion” indicate both miscarriage and abortion, or does it refer to abortion only, or do you mean termination of pregnancy before 20th Weeks of gestation? They imply different meaning in clinical practice. Please clarify.

- “Newborn weight” has 3 sub-groups: underweight, macrosomia and normal weight. Please indicate the weight range for each group.

Figures 2 and 3:

- The standard format for presentation of regression results are “Adjusted OR”, “95% CI”, and “p-value”, each one sits on separate columns. Both lower and upper 95% CIs should be presented in one column for ease of reading. Please reformat the Figures.

Discussion

- “Difficulties and limitations of the study”: you have indicated that “… a lack of data for women with two gestation periods during the same year, where the data could not have been separated;”. Although not unlikely, it is uncommon that one woman gives birth to a preterm/term baby twice in one year. Do you mean both miscarriage/abortion and preterm/term pregnancies? Please clarify.

- What is the implications of the findings in practice? How can the readers use the results of the study to enhance their practice?

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Dr Faiza Alam

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

Dear Editor,

Thank you for your review of the article. Your comments and those of the reviewers have allowed us to introduce some important improvements. I have made the modifications requested, and discuss them in the point-by-point response below.

Sincerely,

Júlia Siscart Viladegut.

Reviewer 1

• Question (Q): The authors write in the limitation that socioeconomic status was not evaluated; however, it was part of the objectives. It should have been included. Overall it is a well-written manuscript. There are no concerns regarding dual publication, research ethics, or publication ethics.

• Answer (A): We have specified in the conclusions that we have not been able to provide the results due to lack of data.

“Finally, we did not have available the data of socio-economical circumstances and environmental factors of the patients, that may also influence the results.” (page 9, line 294-296)

Reviewer 2

• Q: Please indicate at the end of the introduction why you have decided to conduct this study and what is the study significance and what gaps it aimed to address.

• A: We have indicate what you suggest at the end of the introduction.

“We decided to carry out this study because it is important for clinicians to have good epidemiological knowledge of the consequences and comorbidities prevalence on this disease and so they can act in certain way to prevent that.” (page 3, line 106-108)

• Q: In the presented study, pregnancies were groups into low risk, medium risk, high risk and very high risk. Usually in real practice and for the sake of providing appropriate care to each group of women, pregnancies are categorised as “low risk” and “high risk”. Please indicate why you have chosen 4 gropes? Is this what is used in the real practice in the Lleida region to provide care to the women? If not, please clarify and re-group. Please modify the results accordingly.

• A: This classification is what is used in the real practice in Lleida Region Health, on the one hand we can categorised low risk and medium risk as “low risk”. On the other hand we can categorised high risk and very high risk as “high risk”.

• Q: Please provide details of how you chose the criteria for adherence, how you calculated adherence score and what each score (lower/higher) means.

• A: As we have observed in other studies we defined three levels of therapeutic adherence: high, for patients who took more than 80% of the drug prescribed; medium, for those who took between 50 and 80%; and low, for those who took <50%.

o Huber CA, Rapold R, Brüngger B, Reich O, Rosemann T. One-year adherence to oral antihyperglycemic medication and risk prediction of patient outcomes for adults with diabetes mellitus: An observational study. Medicine (Baltimore). 2016 Jun;95(26):e3994. doi: 10.1097/MD.0000000000003994. PMID: 27368004; PMCID: PMC4937918

o Hepp Z, Lage MJ, Espaillat R, Gossain VV. The association between adherence to levothyroxine and economic and clinical outcomes in patients with hypothyroidism in the US. J Med Econ. 2018 Sep;21(9):912-919. doi: 10.1080/13696998.2018.1484749. Epub 2018 Jun 22. PMID: 29865926

• Q: Results: “40.4-64.7% of the treated patients showed high adherence”. Why does adherence for one single group has a range? Please clarify or amend.

• A: We have clarified that. “Specifically, during the years of the study, from 2012 to 2018, the high adherence oscillate between 40.4-64.7% of the treated patients.” (page 6, lines 206-209)

• Q: - “Duration of the pregnancy” has subgroups of “abortion”, “pre-term”, “prolonged”, and “full-term”. Please indicate the gestational age range for each item. Also, does the word “abortion” indicate both miscarriage and abortion, or does it refer to abortion only, or do you mean termination of pregnancy before 20th Weeks of gestation? They imply different meaning in clinical practice. Please clarify.

• A: We have classified the duration of pregnancy as:

o “abortion”: Loss of baby before 20 weeks of gestation.

o “pre-term”: Birth before 36 week of gestation.

o “prolonged”: Birth between 36-40 week of gestation.

o “full-term”: Birth before 40 week of gestation.

In addition, abortion and miscarriage both mean abortion.

• Q: “Newborn weight” has 3 sub-groups: underweight, macrosomia and normal weight. Please indicate the weight range for each group.

• A: We have classified the “Newborn weight” as:

o “underweight”: weight less than 2500g at birth

o “normal weight”: weight between 2500 and 4000g at birth

o “macrosomia” weight more than 4000g at birth

• Q: Figures 2 and 3: - The standard format for presentation of regression results are “Adjusted OR”, “95% CI”, and “p-value”, each one sits on separate columns. Both lower and upper 95% CIs should be presented in one column for ease of reading. Please reformat the Figures.

• A: We have reformatted the figures, as you required us.

• Q: Discussion: - “Difficulties and limitations of the study”: you have indicated that “… a lack of data for women with two gestation periods during the same year, where the data could not have been separated;”. Although not unlikely, it is uncommon that one woman gives birth to a preterm/term baby twice in one year. Do you mean both miscarriage/abortion and preterm/term pregnancies? Please clarify.

• A: We have clarified it at the discussion. “A possible limitation is the lack of data in some participants in our study, such as: women with two gestation periods during the same year, for example the end of the first pregnancy at the beginning of the year and the beginning of the second pregnancy at the end of the same year , where the data could not have been separated;” (page 8, lines 285-288)

• Q: What is the implications of the findings in practice? How can the readers use the results of the study to enhance their practice?

• A: The implications of the findings are explained at the end of conclusions, we have modified it a bit for its better understanding. “For all these reasons, we think that epidemiological knowledge of the disease by the of clinicians can help in early detection early detection and treatment of hypothyroidism, as well as control of therapeutic adherence, can help to prevent its adverse effects in pregnancy and outcomes in offspring” (page 8, lines 302-305)

Decision Letter - Mukhtiar Baig, Editor

PONE-D-22-30145R1Prevalence, risk factors, and consequences of hypothyroidism among pregnant women in the health region of Lleida: a cohort studyPLOS ONE

Dear Dr. Siscart,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Sep 30 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Mukhtiar Baig, Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: All comments have been addressed

Reviewer #3: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Yes

Reviewer #3: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: Yes

Reviewer #3: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

Reviewer #3: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: Many thanks for revising the manuscript!

Please add this description of risk groups to the text “This classification is what is used in the real practice in Lleida Region Health, on the one hand we can categorised low risk and medium risk as “low risk”. On the other hand we can categorised high risk and very high risk as “high risk”.

Please add details of adherence criteria to the text with the respective citations: “As we have observed in other studies we defined three levels of therapeutic adherence: high, for patients who took more than 80% of the drug prescribed; medium, for those who took between 50 and 80%; and low, for those who took <50%”.

The loss of pregnancy before 20th weeks can be abortion or miscarriage depending on the path. In the text, please replace “abortion” with “miscarriage/abortion”.

Figures 2 and 3: The usual format for presenting OR (CI) is up to two decimal points and for p-value is up to three decimal points. To maintain consistency, please revise Figures 2 and 3 accordingly.

Reviewer #3: The discussion section repeats most of the results already mentioned in the results section. It would be good if the discussion is re phrased to elucidate the implications of the findings from the study. Also address any discrepancies and offer insights into potential reasons for unexpected results. Suggestions for mitigation in clinical practice, counselling and future research endeavors should also be mentioned.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

Reviewer #3: Yes: Syeda Sadia Fatima

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 2

Dear Editor,

Thank you for your review of the article. Your comments have allowed us to introduce some important improvements. I have made the modifications requested, and discuss them in the response below.

Sincerely,

Júlia Siscart Viladegut.

Reviewer 2: Many thanks for revising the manuscript!

Question (Q):

Please add this description of risk groups to the text “This classification is what is used in the real practice in Lleida Region Health, on the one hand we can categorised low risk and medium risk as “low risk”. On the other hand we can categorised high risk and very high risk as “high risk”.

Answer (A):

I have added what you asked at methods.

Q:

Please add details of adherence criteria to the text with the respective citations: “As we have observed in other studies we defined three levels of therapeutic adherence: high, for patients who took more than 80% of the drug prescribed; medium, for those who took between 50 and 80%; and low, for those who took <50%”.

A: I add this details at methods.

Q:

The loss of pregnancy before 20th weeks can be abortion or miscarriage depending on the path. In the text, please replace “abortion” with “miscarriage/abortion”.

A: I have replaced the word abortin with miscarriage/abortion.

Q:

Figures 2 and 3: The usual format for presenting OR (CI) is up to two decimal points and for p-value is up to three decimal points. To maintain consistency, please revise Figures 2 and 3 accordingly.

A: Figures 2 and 3 have been revised and submitted again.

Reviewer 3:

Q:

The discussion section repeats most of the results already mentioned in the results section. It would be good if the discussion is re phrased to elucidate the implications of the findings from the study. Also address any discrepancies and offer insights into potential reasons for unexpected results. Suggestions for mitigation in clinical practice, counselling and future research endeavors should also be mentioned.

A: I have modified some parts of the introduction of the discussion section, moreover I have expanded the end of the discussion section with what you suggested.

Decision Letter - Mukhtiar Baig, Editor

Prevalence, risk factors, and consequences of hypothyroidism among pregnant women in the health region of Lleida: a cohort study

PONE-D-22-30145R2

Dear Dr. Siscart,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Mukhtiar Baig, Ph.D.

Academic Editor

PLOS ONE

Formally Accepted
Acceptance Letter - Mukhtiar Baig, Editor

PONE-D-22-30145R2

Prevalence, risk factors, and consequences of hypothyroidism among pregnant women in the health region of Lleida: a cohort study

Dear Dr. Siscart:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Professor Mukhtiar Baig

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .